Canaccord says Momenta Pharmaceuticals (MNTA +1.3%) risk/reward looks favorable going into the...

|About: Momenta Pharmaceuticals, Inc. (MNTA)|By:, SA News Editor

Canaccord says Momenta Pharmaceuticals (MNTA +1.3%) risk/reward looks favorable going into the generic Copaxone suit - which is expected to be resolved in H212. Canaccord thinks consensus is only factoring in a 25% chance of a win for MNTA and its sees more upside potential.